Day One Biopharmaceuticals (DAWN) Projected to Post Earnings on Tuesday

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data after the market closes on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.45) per share and revenue of $30.28 million for the quarter.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The company had revenue of $29.21 million during the quarter, compared to analysts' expectations of $27.11 million. On average, analysts expect Day One Biopharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Day One Biopharmaceuticals Stock Performance

Day One Biopharmaceuticals stock opened at $7.74 on Tuesday. Day One Biopharmaceuticals has a fifty-two week low of $6.41 and a fifty-two week high of $18.07. The firm has a market capitalization of $784.48 million, a price-to-earnings ratio of -7.51 and a beta of -1.24. The stock's fifty day moving average is $8.27 and its two-hundred day moving average is $11.53.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. JPMorgan Chase & Co. dropped their target price on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an "overweight" rating for the company in a report on Wednesday, March 5th. Needham & Company LLC restated a "buy" rating and set a $32.00 price objective on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Wedbush reiterated an "outperform" rating and set a $32.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday, February 26th. The Goldman Sachs Group decreased their price objective on Day One Biopharmaceuticals from $39.00 to $27.00 and set a "buy" rating on the stock in a research note on Tuesday, March 25th. Finally, HC Wainwright reissued a "buy" rating and issued a $36.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, April 3rd. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Day One Biopharmaceuticals presently has an average rating of "Buy" and an average price target of $32.29.

Insider Activity

In related news, General Counsel Adam Dubow sold 4,646 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $55,566.16. Following the transaction, the general counsel now directly owns 39,602 shares in the company, valued at $473,639.92. This trade represents a 10.50 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jeremy Bender sold 12,048 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total value of $144,094.08. Following the sale, the chief executive officer now owns 128,015 shares in the company, valued at $1,531,059.40. The trade was a 8.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 21,064 shares of company stock valued at $251,925. Company insiders own 6.20% of the company's stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.